Our next-generation in vivo immunotherapy

Stimulated-Ghost-Cells innovation

Our product

Tackling tumor heterogeneity

Data-driven selection

Selection of well-characterized allogeneic human cell lines that reflect the heterogeneity of the targeted indication and represent patient diversity — including key mutations and different phenotypic profiles.

Tackling tumor heterogeneity

Revealing resistance and plasticity mechanisms

Mimicking stress conditions of relapsing patients

Stimulation by standards of care and physical stressors to reveal over 200 cancer-related proteins.
These proteins represent tumor specificity, plasticity, and resistance mechanisms, validated through proteogenomic and predictive modeling.

Tackling tumor heterogeneity

Revealing resistance and plasticity mechanisms

Making it visible

Immune “flare” + ghost cell inactivation

In vitro haptenation flags non-visible cancer-related anitgens to boost their recognition in vivo, by innate immune system. Final inactivation in ghost cells supporting haptenatedproteins and ensuring a safe in vivo education of the immune system.

Data-driven selection

Mimicking stress conditions of relapsing patients

Stimulation by standards of care and physical stressors to reveal over 200 cancer-related proteins. 

These proteins represent tumor specificity, plasticity, and resistance mechanisms, validated through proteogenomic and predictive modeling.

Immune “flare” + ghost cell inactivation

In vitro haptenation flags non-visible cancer-related anitgens to boost their recognition in vivo,

by innate immune system. Final inactivation in ghost cells supporting haptenated proteins and ensuring a safe in vivo education of the immune system.

How it works

We initiate a multi-specific in vivo immune response against tumor

1. Captation by APCs under the derm

Potentiates dendritic cell functions

APC: Antigen Presenting Cells

1. Captation by APCs under the derm

2. In vivo immune cells priming and activation

Cancer antigens cross presentation

MHC: Major histocompatibility complex

1. Captation by APCs under the derm

2. In vivo immune cells priming and activation

3. Immune cells expansion

Expansion of the educated multi-specific T cell populations

1. Captation by APCs under the derm

2. In vivo immune cells priming and activation

3. Immune cells expansion

4. Recognition, infiltration and destruction of tumor cells

Biological rational to synergize with immune checkpoint inhibitors

Our platform

Our products are developed using our ready-to-use therapeutic platform, designed to generate first-in-class immunotherapies

Our advantages

Anticipating tumor evolution from 1st line to overcome current limitations

product

UNMET NEED – WORLDWIDE

other
indications

colorectal
cancer

other indications

colorectal cancer

ovarian
cancer

ovarian cancer

BreAK CRC 001 Study Design NCT06934538

Open label, multicenter, dose-escalation and cohort-expansion phase I/IIA trial of STC-1010 in patients with unresectable locally advanced or metastatic colorectal cancer (CRC) in first line setting

Our next-generation in vivo immunotherapy

Tackling tumor heterogeneity

Data-driven selection

Tackling tumor heterogeneity

Revealing resistance and plasticity mechanisms

Mimicking stress conditions of relapsing patients

Tackling tumor heterogeneity

Revealing resistance and plasticity mechanisms

Making it visible

Immune “flare” + ghost cell inactivation

Hapten

Carrier

Data-driven selection

Mimicking stress conditions of relapsing patients

Immune “flare” + ghost cell inactivation

Hapten

Carrier

We initiate a multi-specific in vivo immune response against tumor

1. Captation by APCs under the derm

1. Captation by APCs under the derm

2. In vivo immune cells priming and activation

1. Captation by APCs under the derm

2. In vivo immune cells priming and activation

3. Immune cells expansion

1. Captation by APCs under the derm

2. In vivo immune cells priming and activation

3. Immune cells expansion

4. Recognition, infiltration and destruction of tumor cells

Captation by APCs under the derm

In vivo immune cells priming and activation

Immune cells expansion

Recognition, infiltration and destruction of tumor cells

Our products are developed using our ready-to-use therapeutic platform, designed to generate first-in-class immunotherapies

Reproducing in vivo tumor heterogeneity

Neoantigens and cancer proteins validation

Advanced antigens presentation methods

Standardized & Scalable manufacturing process

STC-1010

STC-1020

STC-10XX

Anticipating tumor evolution from 1st line to overcome current limitations

mCRC IL MSS: 95% of patients

mCRC 2L MSI-H: 5% of patients

Combo: checkpoint inibitors

Pancreatic - PDAC

Liver disease - HCC

STC-1020 + Adjuvant

BreAK CRC 001 Study Design NCT06934538

Our awards